Case Summary:     

With NAILG’s support, a computational chemistry researcher has secured EB-1A approval for his exceptional achievements and influential contributions to the field of computer-aided drug design and cheminformatics. Holding a Ph.D. in computational chemistry, he is recognized as one of the few leading experts advancing both theory and application in this critical area. His work is especially well known for investigating how epigallocatechin gallate (EGCG) interacts with the intrinsically disordered N-terminal domain of protein p53 and disrupts the interaction between p53 and MDM2, findings that have broad implications for the development of innovative cancer therapeutics.

Through this line of inquiry, he has consistently contributed new knowledge and novel methods that push the boundaries of computational modeling in chemistry. His proposed endeavor is to continue advancing computational techniques that accelerate drug discovery, enhance therapeutic development, and ultimately improve healthcare outcomes in the United States, an area of research with both substantial merit and national importance.

His publication record reflects the significant impact of his work. He has authored 18 peer-reviewed scientific articles, including 7 as first author. These studies have already been cited 1,115 times according to Google Scholar, a clear demonstration that his findings are being actively utilized and built upon by other researchers worldwide. Beyond publications, he has completed at least 25 peer reviews, a role entrusted only to respected experts whose insight is valued by leading journals.

His accomplishments have been further validated through major funding support from prestigious organizations such as the National Institutes of Health (NIH), the National Natural Science Foundation of China, and the Sichuan Provincial Department of Science and Technology. This backing not only underscores the quality of his research but also highlights its alignment with global priorities in drug design and therapeutic innovation.

The petition was further strengthened by four letters of recommendation from distinguished experts in the field, each affirming the originality, influence, and wide-ranging applicability of his work.
“[Client] is a highly skilled computational chemist with a strong background that has equipped him well to succeed in his research endeavors.”

Despite the rigorous standards of the EB-1A category, USCIS agreed that his record demonstrated the sustained acclaim and extraordinary ability required for approval. This success is both a recognition of his past accomplishments and an affirmation of his future potential to continue transforming computational chemistry and drug design. NAILG is proud to have assisted in securing this well-deserved approval and looks forward to his continued contributions to science and healthcare innovation.